Available Technologies - Search Results
| Title: | Platelet Aggregation Inhibitors |
|---|---|
| UC Case No: | 2001-089-2-ott |
| Categories: |
Veterinary:
Animal Health
Chemical: Compositions Pharmaceuticals: Cardiovascular, Cardiovascular, Immune and Inflammatory Disorders Biotechnology: Drug Production and Design, Drug Targets and Screening Tools, Gene and Cell Therapy, Genomics and Proteomics, Protein Folding and Interactions, Research Tools |
| Background: | Thrombin is an enzyme in the blood that plays a key role in platelet formation during injury. While blood coagulation is essential for a surface wound, platelet activation underlies various pathological situations such as unstable angina pectoris, myocardial infarction and stroke. Thrombin is mediated by protease activated receptor-1 (PAR-1) which is expressed in the nervous system and in platelets. Once activated by thrombin, PAR-1 induces rapid and dramatic changes in cell morphology that is controlled by a series of localized ATP-dependent reactions. |
| Technology: | Researchers at the University of California have discovered specific creatine kinase inhibitors that inhibit thrombin-induced aggregation of platelets. These creatine kinase inhibitors could be used to treat a disease or disorder that is caused by pathological platelet aggregation. |
| Application: | This treatment has applications both for humans and in veterinary medicine. |
| Contact: |
Maria Tkachuk, Licensing Associate Office of Technology Alliances University of California, Irvine 380 University Tower Irvine, CA 92697-7700 Phone: (949) 824-2288 FAX: (949) 824-2899 Email: mtkachuk@uci.edu |
| Patent Status: | U.S. Patent No. 6,444,695 |
| UCI School: | College of Medicine |
| Department: | Microbiology & Molecular Genetics |
